[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557410":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":43,"collaborators":7,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Shin-young Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[15,30],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":7,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Chung-Ang University Hospital","RECRUITING","Seoul","06973","South Korea",{"type":22,"coordinates":23},"Point",[24,25],126.9784,37.566,{"lat":25,"lon":24},[28],{"name":29,"role":11,"phone":7,"phoneExt":7,"email":7},"Min Kyoon Kim",{"facility":31,"status":32,"city":33,"state":7,"zip":34,"country":20,"countryCode":7,"cosmosGeoPoint":35,"geoPoint":39,"contacts":40},"Uijeongbu Eulji Medical Center, Eulji University","NOT_YET_RECRUITING","Uijeongbu-si","11759",{"type":22,"coordinates":36},[37,38],127.0474,37.7415,{"lat":38,"lon":37},[41],{"name":42,"role":11,"phone":7,"phoneExt":7,"email":7},"Byung Joo Song",{"type":44,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100557410",false,"NCT06537752","A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients","A Multi-center, Prospective, Observational stuDy to Evaluate EThanOl-induced Symptoms and Safety in Breast Cancer Patients witH Neoadjuvant\u002FAdjuvant Chemotherapy Including Non-ethanol Formulation Docetaxel Before and After Surgery","Inclusion Criteria:\n\n* Those who voluntarily signed a written personal information collection and usage agreement after receiving an explanation about the objective and method, etc. of this clinical study.\n* Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable.\n\n  * Those who need neoadjuvant chemotherapy as breast cancer patients\n  * Those who need adjuvant chemotherapy after breast cancer surgery\n* Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Those are diagnosed with other primary cancer that can influence the treatment or prognosis of primary breast cancers.\n* Those are diagnosed with secondary breast cancers.\n* Those with Stage 0\u002F1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.","FEMALE","19 Years",{"count":54,"type":55},1052,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant\u002Fadjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery",[59],"Breast Cancer","2025-09-10",{"date":62,"type":63},"2025-09-12","ACTUAL",{"date":65,"type":63},"2024-07-15",{"date":67,"type":55},"2026-10",{"name":5,"class":6},2]